The best period of stock performance in this company's history was when Revlimid was just coming on board. Even as its brilliant potential foreshadowed a remarkable future for this company, shortsighted investors found something to fret about in earnings numbers from thalomid sales, and missed the boat.
Revlimid meet expectations for Q4. But the fact that Hugin foresees a Q1 filing for Pomalidomide and dramatic advancement for Apremilast foreshadows a remarkable future for this company, and the stock is about to embark on another period of stunning performance. Shortsighted investors who find something to fret about in earnings numbers will miss the boat, again.
To those whining about the small gains so far this morning - Celgene never performs well immediately after an earnings call, and indeed is usually down, often significantly. It always rallies by the end of the day and over the next several weeks.
This is a stock trading at 14.5x 2012 earnings, about 1/2 its growth rate, with SO MANY LIKELY EARNINGS CATALYSTS not yet included in forecasts. And, as Hugin said, at JPM next year, he expects to be talking mostly about Pomalidomide and Apremilast - and NOTHING for them is yet included in any forecasts.
This stock may go through the 70s without a pit stop.